Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
Mvasi (bevacizumab-awwb) is a biosimilar to the anti-VEGF antibody Avastin (bevacizumab), which binds to and inhibits VEGF, resulting in decreased tumor growth and angiogenesis (PMID: 29743182). Mvasi (bevacizumab-awwb) is FDA approved for use in combination with chemotherapy in colorectal cancer, in combination with carboplatin and paclitaxel in non-squamous non-small cell lung cancer, in glioblastoma, in combination with interferon-alfa in renal cell carcinoma, and in combination with paclitaxel and cisplatin or topotecan in cervical cancer (FDA.gov).
|DrugClasses||VEGF Antibody 10|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Bevacizumab-awwb + Carboplatin + Paclitaxel||Bevacizumab-awwb Carboplatin Paclitaxel||0||0|
|Bevacizumab-awwb + Sotorasib||Bevacizumab-awwb Sotorasib||0||1|